文献速递胸部肿瘤放疗

立体定向消融放疗对比常规分割放疗治疗I期小细胞肺癌

Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2018-12-31

基于美国国家癌症数据库分析2107例接受化疗的T1-2N0M0小细胞肺癌患者,其中7.1%接受立体定向消融放疗(SABR)/化疗,92.9%接受常规分割放疗(CFRT)/化疗,两组中位生存分别为29.2个月与31.2个月(p=0.77),倾向性匹配后分别为25.4个月与34.3个月(p=0.85),多因素分析显示放疗技术方式与总生存无关(p=0.95)。

要点

  • 在I期小细胞肺癌中,SABR/化疗与CFRT/化疗的总生存差异无统计学意义。
  • SABR/化疗组患者更多为高龄、T1期、在学术/整合网络机构治疗及近年治疗者(p均<0.05)。
  • 作者认为,鉴于随机研究难以入组,这些回顾性数据应被强烈考虑用于将SABR/化疗作为该人群的首选方案。

核心结论

  • 对于I期小细胞肺癌,SABR/化疗与CFRT/化疗相比提供了统计学上等效的结局。
  • 作者认为,由于针对这一少见情况的随机研究几乎肯定面临入组不足,这些回顾性数据应被强烈考虑用于将SABR/化疗作为该人群的首选方案。

研究设计与样本

  • 查询美国国家癌症数据库,纳入组织学确诊的T1-2N0M0小细胞肺癌患者,所有患者均接受化疗。
  • 采用多因素logistic回归分析确定与SABR/化疗相关的因素,采用Kaplan-Meier法评估总生存,采用多因素Cox比例风险模型分析与总生存相关的因素,并在倾向性匹配后计算生存。
  • 共纳入2107例患者,其中7.1%接受SABR/化疗,92.9%接受CFRT/化疗。

主要发现

  • SABR的中位(四分位距)剂量为50(48-54)Gy,分4(3-5)次;CFRT为55.8(45-60)Gy,分30(30-33)次。
  • 接受SABR/化疗的患者更多为高龄、T1期疾病、在学术/整合网络机构治疗以及近年治疗(p均<0.05)。
  • 两组中位生存分别为29.2个月与31.2个月(p=0.77),倾向性匹配后分别为25.4个月与34.3个月(p=0.85)。
  • 多因素分析显示,放疗技术方式与总生存无关(p=0.95)。

临床怎么用

  • 作者认为,这些回顾性数据应被强烈考虑用于将SABR/化疗作为I期小细胞肺癌人群的首选方案。

局限性

  • 作者指出,针对这一少见情况的随机研究几乎肯定面临入组不足。
  • 本研究为回顾性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The National Comprehensive Cancer Network (NCCN) recently revised recommendations for inoperable stage I small cell lung cancer (SCLC), having added stereotactic ablative radiotherapy (SABR)/chemotherapy to the historical paradigm of concurrent conventionally-fractionated radiation therapy (CFRT)/chemotherapy. Despite the conformality, convenience, and cost-effectiveness of SABR, the NCCN continues to recommend both CFRT/chemotherapy and SABR/chemotherapy primarily because these approaches have not been comparatively analyzed to date. METHODS: The National Cancer Database was queried for histologically-confirmed T1-2N0M0 SCLC; all patients received chemotherapy. Multivariable logistic regression ascertained factors associated with SABR/chemotherapy. Kaplan-Meier analysis assessed overall survival (OS); multivariable Cox proportional hazards modeling examined factors associated with OS. Survival was also calculated following propensity matching. RESULTS: Of 2,107 patients, 7.1% underwent SABR/chemotherapy, and 92.9% received CFRT/chemotherapy. The median (interquartile range) dose of SABR was 50 (48-54) Gy in 4 (3-5) fractions, and 55.8 (45-60) Gy in 30 (30-33) fractions for CFRT. Patients receiving SABR/chemotherapy were more often older, had T1 disease, treated at academic/integrated network facilities, and managed in more recent years (p < 0.05 for all). Respective median survival figures were 29.2 versus 31.2 months (p = 0.77), which persisted following propensity matching (25.4 versus 34.3 months, p = 0.85). On multivariable analysis, radiotherapeutic technique was not associated with OS (p = 0.95). CONCLUSIONS: For stage I SCLC, SABR/chemotherapy affords statistically equivalent outcomes to CFRT/chemotherapy. Because randomized studies addressing this uncommon scenario would almost certainly suffer from inadequate accrual, these retrospective data should be strongly considered in efforts to institute SABR/chemotherapy as the preferred option for this population.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Verma V, Hasan S, Wegner RE, et al. Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer. Radiother Oncol. 2018. PMID: 30773182. doi:10.1016/j.radonc.2018.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。